Trial Profile
Entecavir for the treatment of breakthrough hepatitis caused by lamivudine and adefovir dipivoxil-resistant mutants of hepatitis B virus
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 31 Aug 2015
Price :
$35
*
At a glance
- Drugs Entecavir (Primary)
- Indications Hepatitis B
- Focus Therapeutic Use
- 30 Aug 2015 Status changed from recruiting to discontinued as per University Hospital Medical Information Network - Japan record.
- 09 Oct 2012 New trial record